f Immune Checkpoint Protein for Monitoring Head and Neck Cancer Prognosis

References

1. WangC.W. BiswasP.K. IslamA. ChenM.K. ChuehP.J. The use of immune regulation in treating head and neck squamous cell carcinoma (HNSCC).Cells202413541310.3390/cells13050413
   [Google Scholar]
2. De FeliceF. PrannoN. MaramponF. MusioD. SalducciM. PolimeniA. TomboliniV. Immune check-point in glioblastoma multiforme.Crit. Rev. Oncol. Hematol.2019138606910.1016/j.critrevonc.2019.03.019 31092387
   [Google Scholar]
3. ProdeusA. Abdul-WahidA. FischerN.W. HuangE.H.B. CydzikM. GariépyJ. Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers.Mol. Ther. Nucleic Acids201544e23710.1038/mtna.2015.11 25919090
   [Google Scholar]
4. MummareddyS. PradhanS. NarasimhanA. NatarajanA. On demand biosensors for early diagnosis of cancer and immune checkpoints blockade therapy monitoring from liquid biopsy.Biosensors (Basel)2021111250010.3390/bios11120500 34940257
   [Google Scholar]
5. El-KhoueiryA.B. SangroB. YauT. CrocenziT.S. KudoM. HsuC. KimT.Y. ChooS.P. TrojanJ. WellingT.H.III MeyerT. KangY.K. YeoW. ChopraA. AndersonJ. dela CruzC. LangL. NeelyJ. TangH. DastaniH.B. MeleroI. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017389100882492250210.1016/S0140‑6736(17)31046‑2 28434648
   [Google Scholar]
6. IncorvaiaL. FanaleD. BadalamentiG. PortaC. OliveD. De LucaI. BrandoC. RizzoM. MessinaC. ReditiM. RussoA. BazanV. IovannaJ.L. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: A step toward a biomarker for therapeutic decisions.OncoImmunology202091183234810.1080/2162402X.2020.1832348 33178494
   [Google Scholar]
7. NociniR. VianiniM. GirolamiI. CalabreseL. ScarpaA. MartiniM. MorbiniP. MarlettaS. BrunelliM. MolteniG. ParwaniA. PantanowitzL. EccherA. PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.Clin. Exp. Dent. Res.20228369069810.1002/cre2.590 35593124
   [Google Scholar]